key: cord-0781435-6u4kimz4
authors: Ozelo, Margareth C.; Yamaguti‐Hayakawa, Gabriela G.
title: Impact of novel hemophilia therapies around the world
date: 2022-04-12
journal: Res Pract Thromb Haemost
DOI: 10.1002/rth2.12695
sha: d6e9a53160953fceeba51e3c9e01b41641dc2d86
doc_id: 781435
cord_uid: 6u4kimz4

Hemophilia A and B are hereditary bleeding disorders, characterized by factor VIII or IX deficiencies, respectively. For many decades, prophylaxis with coagulation factor concentrates (replacement therapy) was the standard‐of‐care approach in hemophilia. Since the 1950s, when prophylaxis started, factor concentrates have been improved with virus inactivation and molecule modification to extend its half‐life. The past years have brought an intense revolution in hemophilia care, with the development of nonfactor therapy and gene therapy. Emicizumab is the first and only nonreplacement agent to be licensed for prophylaxis in people with hemophilia A, and real‐world data show similar efficacy and safety from the pivotal studies. Other nonreplacement agents and gene therapy have ongoing studies with promising results. Innovative approaches, like subcutaneous factor VIII and lipid nanoparticles, are in the preclinical phase. These novel agents, such as extended half‐life concentrates and emicizumab, have been available in resource‐constrained countries through the constant efforts of the World Federation of Haemophilia Humanitarian Aid Program. Despite the wide range of new approaches and therapies, the main challenge remains the same: to guarantee treatment for all. In this article, we discuss the evolution of hemophilia care, global access to hemophilia treatment, and the current and future strategies that are now under development. Finally, we summarize relevant new data on this topic presented at the ISTH 2021 virtual congress.

Hemophilia A and B are congenital X-linked bleeding disorders caused by factor VIII (FVIII) or factor IX (FIX) deficiency, respectively. Clinical manifestation correlates with the residual endogenous clotting factor activity. People with FVIII or FIX plasma levels of <1 IU/dL are classified as having severe hemophilia and may have spontaneous bleeding events. In moderate (1-5 IU/dL) and mild (5 to ≤40 IU/dL) hemophilia, 1 bleeding symptoms are usually associated with trauma or surgical procedures. In hemophilia, the most frequent bleeds occur in joints and muscles, resulting in chronic and progressive arthropathy with significant crippling morbidity. In addition, there is a risk of life-threatening bleeding, such as intracranial hemorrhage, particularly in people with severe phenotype, in the absence of adequate treatment. 2 Since the 1950s, several significant achievements have happened for hemophilia A and B, resulting in considerable improvements in hemophilia care and patient quality of life ( Figure 1 ). Among these, the main improvement is the availability of safe options to replace the missing clotting factor and restore hemostasis. The so-called replacement therapy, using plasma-derived or recombinant products, has been considered the cornerstone for hemophilia treatment and ensures the adoption of prophylactic therapy. 2, 3 However, even with the progress achieved with bioengineered clotting factors, including extended half-life (EHL) FVIII or FIX products, replacement therapy is costly, requires burdensome frequent intravenous injections, and has the risk for development of inhibitors. 2 These factors compromise adherence and access to adequate treatment for people with hemophilia worldwide.

New products have recently been developed. Nonreplacement therapies, including emicizumab and rebalancing products, are transforming the approach for hemophilia treatment. These products are administered subcutaneously and are effective prophylactic options, regardless of the presence of inhibitors. More recently, adeno-associated virus (AAV) vector-mediated gene therapy trials for hemophilia A and B have presented promising results. 2, 3 Despite the several new options and strategies for hemophilia care, access to treatment still represents a critical challenge for most people with hemophilia worldwide 4 and more needs to be done to guarantee adequate treatment for all people with hemophilia. In this article, we discuss the evolution of hemophilia care, the access to hemophilia treatment worldwide, and the current and future strategies that are now under development. Finally, we summarize relevant new data on this topic presented at the ISTH 2021 virtual congress.

Until the early 1960s, the only available treatment for hemophilia was based on whole blood or fresh plasma transfusion, which was insufficient to avoid most bleeding complications. Consequently, most people with severe hemophilia died in childhood and early adulthood. 3 In 1958, Inga Nilsson and colleagues in Malmo, Sweden, were pioneers to use the regular prophylactic infusion of a local F I G U R E 1 Hemophilia care evolution. (A) Evolution of hemostatic agents. (B) Improvement in hemophilia care. Abbreviations: anti-APC, anti-activated protein C; anti-TFPI, anti-tissue factor pathway inhibitor; aPCC, activated prothrombin complex concentrate; AT siRNA, small interfering RNA targeting antithrombin; DDAVP, desmopressin; EHL rFVIII, extended half-life recombinant factor VIII concentrate; EHL rFIX, extended half-life recombinant factor IX concentrate; Emi, emicizumab; HA GT, hemophilia A gene therapy; HB GT, hemophilia B gene therapy; PCC, prothrombin complex concentrate; pdFIX, plasma-derived factor IX concentrate; pdFVIII, plasma-derived factor VIII concentrate; RCT, randomized controlled trial; rFIX, recombinant factor IX concentrate; rFVIII, recombinant factor VIII concentrate factor human fraction I-0 (antihemophilic factor concentrate) containing FVIII to convert the bleeding phenotype temporarily from severe to moderate, resulting in a significant decrease in bleeding episodes and reduction of the impact of arthropathy, particularly when started at an early age. 5 Nevertheless, only after the advent of cryoprecipitate 6 and, later, lyophilized plasma-derived FVIII and FIX concentrates, did home treatment become possible, a crucial step to guarantee the early treatment of the bleeding episodes and regular prophylaxis. 7 However, the first plasma-derived clotting factor concentrates had no viral inactivation methods applied to their manufacturing process. It was only in 1985 that these methods were incorporated, reducing the risk of blood-borne infections drastically. 3 Meanwhile, the cloning of FVIII and FIX genes (in 1982 and 1984, respectively) enabled the development of virus-free recombinant FVIII and FIX concentrates. 8 The availability of safe FVIII and FIX products contributed to the evolution of prophylaxis as a feasible treatment modality. The benefits of prophylaxis have been recognized since the first publications. However, primary prophylaxis became the evidence-based standard of care for hemophilia after results from a randomized clinical trial conducted by Manco-Johnson et al. 9 In fact, prophylaxis is preferable to episodic treatment, even when using a lower dose of factor concentrates. Long-term prophylaxis is recognized as the standard of care for all people with hemophilia with severe clinical phenotype 10 and has been proven to be effective in preventing lifethreatening bleeds and joint damage 9 (Figure 1 ).

For many decades, hemophilia treatment was based on replacement therapy using plasma-derived clotting factors or recombinant products. However, advancing technology made it possible to develop unmodified recombinant products with a standard half-life (SHL), and clotting factor concentrates with EHL. 3 EHL clotting factor concentrates are bioengineered molecules with increased half-life by at least 1.3 times over that of SHL FVIII or FIX concentrates. 11 Different technologies were used for the development of EHL products. These include the conjugation with polyethylene glycol and fusion with other proteins, such as albumin and or the fragment crystallizable (Fc) of IgG1. Table 1 summarizes the characteristics of the currently licensed EHL products.

EHL products were developed to lead to higher factor peaks and trough levels, decreasing the frequency of intravenous injections and reducing the burden of prophylaxis. These strategies to improve pharmacokinetic (PK) parameters resulted in a significant extension of FIX concentrates half-life, usually 3 to 5 times longer than SHL-FIX products. [12] [13] [14] [15] [16] However, EHL-recombinant FVIII (rFVIII) products achieved only 1.5 to 1.8 times longer half-life than SHL-FVIII products [17] [18] [19] [20] [21] [22] [23] [24] This minor improvement in PK parameters is probably due to the function of von Willebrand factor (VWF). In the circulation, FVIII needs to be bound to VWF for stabilization. Therefore, the maximum half-life achieved by EHL-rFVIII products is the same as VWF's half-life. 25 More recently, a new EHL-rFVIII product has been under devel- 

Although replacement therapy has been the standard therapeutic option to repair the hemostatic defect in hemophilia for several decades, it has limitations and challenges. That includes the burden from recurrent intravenous infusions, which compromises the adherence and, as a result, the efficacy of prophylactic treatments, even using EHL products. In this context, nonreplacement therapies could fulfill these unmet needs in hemophilia care. 2 Nonreplacement therapy is a class of products developed using strategies beyond the concept of replacing the deficient clotting factor. These novel agents aim to either restore the hemostasis using mimetic products or establish the rebalance of the hemostasis, inhibiting the anticoagulant pathways. In addition, these nonreplacement products are administered subcutaneously, overcoming the burden associated with frequent intravenous administration. The subcutaneous route can be particularly exciting when caring for young children or patients with poor venous access. These agents also address the challenging scenario of managing patients with neutralizing anti-FVIII or anti-FIX antibodies (inhibitors), whose bleeding episodes are more frequent and difficult to control ( Table 2 ).

In this setting, the approach to substitute rather than replace FVIII was highly successful. Emicizumab is the first nonreplacement therapy approved for prophylaxis in patients with hemophilia A with and without inhibitors. It is a humanized bispecific monoclonal antibody with binding sites to activated factor IX and factor X, mimicking FVIII in its cofactorial activity. 27 A series of emicizumab pivotal clinical trials (HAVEN 1-4) have confirmed efficacy and safety for children and adults with hemophilia A, with and without inhibitors. [27] [28] [29] [30] [31] These trials have also reported a significant impact on the quality of life for both children and adults. Efficacy and safety in the pediatric population were also confirmed in HOHOEMI trial, which included children as young as 4 months old. 32 Reports from different hemophilia centers have confirmed the safety reported in the pivotal studies but observed a higher risk of breakthrough bleeds in older people. 33 Prophylaxis with emicizumab in previously untreated people is still under debate, while the incidence and consequences of anti- Emicizumab also had a positive impact on the challenging scenario of periprocedural management. In the past few years, many reports with real-world data have shown the safety of managing minor and major procedures in people with and without inhibitors. 33, 34 Currently, we observe a learning curve for both patients and clinicians has advanced since emicizumab was licensed for people with hemophilia A. This disruptive approach to hemophilia also changed the way bleeds are identified and treated. Therefore, data on realworld use, including bleeding and periprocedural management, is essential to build knowledge outside clinical trials. Societies and groups of experts have also issued guidelines on bleeding treatment, perioperative management, and laboratory surveillance for emicizumab. [35] [36] [37] [38] Other unanswered questions come from scenarios where emicizumab probably does not fully substitute FVIII. One of them is bone metabolism and health. The EmiMK study will evaluate bone health in patients under emicizumab (NCT04131036). Prophylaxis for sports is another intriguing scenario to be addressed in the STEP study, where emicizumab and FVIII concentrates will be compared for prophylaxis for provoked bleeding (NCT05022459).

Emicizumab use in other populations is also currently under evaluation in clinical trials. HAVEN 6 is designed to evaluate prophylaxis with emicizumab in people with mild and moderate hemophilia A without inhibitors (NCT04158648). Another ongoing trial will address the efficacy of prophylaxis with emicizumab in acquired hemophilia A (NCT04188639). 

Hemophilia has always been an attractive candidate for gene therapy. For decades, hemophilia gene therapy research groups have been dedicated to finding the ideal strategy for achieving lasting plasma factor levels with a one-time treatment. Current gene therapy clinical trials for hemophilia are using the same strategy. They are based on intravenous administration of the liver-directed delivery of FVIII or FIX transgene using recombinant nonintegrating AAV vectors ( Figure 2A ).

The first AAV liver-directed gene therapy clinical trial for hemophilia B was critical to establish the current successful strategies. 48 This study used an AAV2 vector administered into the hepatic artery and revealed essential issues related to AAV vector immunogenicity. One was associated with the preexisting immunity due to In 2011, the first successful liver-directed AAV vector-based gene therapy for hemophilia B was reported, with two critical strategies for AAV immunogenicity management. 49 therapy still needs to be determined. In addition, safety concerns due to integration and potential malignancy risk will need long-term follow-up. 57 However, long-term durability seems to be another bold challenge, particularly for hemophilia A gene therapy. 52, 67 After initial phase 1 and 2 trials confirming safety and exploring efficacy outcomes, more extensive phase 3 clinical trials for hemo- 

Despite the significant advances in hemophilia care in the last decades, access to adequate diagnosis and treatment is still considerably unbalanced.

FVIII usage per capita is a critical parameter that has been used to estimate access to clotting factor products for years. Although the consumption of new nonfactor products will require consid- 

In 1996, WFH started the Humanitarian Aid Program, an important initiative to provide access to treatment for people with inherited bleeding disorders in resource-constrained countries. Nevertheless, until 2014, the donations of procoagulant products were limited and sporadic, and its use was restricted to emergencies since there were not enough factor concentrates to provide sustained on-demand treatment. 4 However, in 2014, pharmaceutical companies Sanofi (formerly Biogen and Bioverativ) and Sobi announced the donation of 1 billion IU of EHL FVIII and FIX concentrates over 10 years. 4 As a result of this expressive increase in donated products through the WFH Humanitarian Aid Program, it was possible to expand the goals and number of people and countries that benefit from this initiative.

Since 2016, donated EHL products have provided low-dose prophylaxis for people from resource-constrained countries. In 2016, the number of people on prophylaxis with donated products rose from 0 to 852, with 458 people <10 years old. 4 In 2020, the cumulative number of people on prophylaxis with donated products was 1804 (including 1145 people <10 years old). 78 The Humanitarian Aid

Program helped expand the use of EHL products worldwide for prophylaxis 79 and surgical procedures. 4, 80 Several pharmaceutical companies continue to help increase access to treatment through the Humanitarian Aid Program.

Despite the challenges and logistical restrictions with the COVID-19 pandemic, the program was not interrupted and was crucial to guarantee access to treatment for people in 69 countries in 2020. 78 In 2019, Roche also became a contributor to the program and, in 2020, started to donate emicizumab. 78 

Almost 4 years after its first approval, real-world data elucidated emicizumab's performance outside controlled clinical trials. The had completed the extension period when the data were presented.

As for efficacy, the ABR was 6.4 for hemophilia A without inhibitors, This strategy resulted in a good availability (up to 18.5%) for subcutaneous human recombinant FVIII, with slow absorption and prolonged half-life. 96 As previously discussed, AAV vectors are widely used in gene transfer clinical trials for hemophilia A and B. Among its many benefits, AAV vectors are replication defective and target many different cells and tissues. Nevertheless, the unpredictable postinfusion response and the slow but progressive loss of expression over the years are still issues to be addressed. In this scenario, lentiviral vectors emerge as interesting candidates for gene transfer with long-term expression. Since lentivirus integrates into the host's cell chromatin, its genome is maintained after each cellular duplication.

Preclinical studies have shown multiyear transgene liver expression in mice and dogs with hemophilia A. 97, 98 More recently, some improvements in lentiviral vectors have been studied. Modifications in the vector surface to decrease T-cell-mediated immunogenicity and increased resistance to phagocytosis have led to higher FIX expression, reaching values up to 300% of normal. 99 Beyond viral vectors, lipid nanoparticles are also being studied for gene transfer. Chen et al 100 have described the use of FVIIIencoding mRNA, packaged into liver-directed lipid nanoparticles.

After a single intravenous injection, hemophilia A mice have presented with a variable range of FVIII activity and maintained therapeutic FVIII levels up to 5 to 7 days after infusion.

Remarkable improvement in hemophilia care was achieved during the past decades. The availability of safe and effective clotting factor concentrates was crucial for prophylaxis feasibility, starting at a young age for people with severe hemophilia. New bioengineered clotting factors, such as EHL products, helped ameliorate the burden of frequent intravenous administration. However, the risk for inhibitors continues to be the major complication of hemophilia replacement therapy.

More recently, the development of nonreplacement therapies represents a unique alternative in the effective prevention of bleeding, regardless of the presence of inhibitors. Currently, emicizumab has become the preferable option for prophylaxis for people with hemophilia A with inhibitors, with several advantages for people with noninhibitor hemophilia A. These new therapies have also been used in resource-constrained countries through the WFH Humanitarian

Aid Program and contributed to increasing the chance of elective surgeries and the number of people on prophylaxis in low-income countries.

In addition, gene therapy clinical trials for hemophilia have shown promising results, and this modality of treatment may become an attractive alternative for hemophilia management, even in resourceconstrained countries.

Thus, in the near future, one of the recurrent challenges for hemophilia management will be to define the most appropriate treatment according to the needs of each person and local treatment availability.

We thank Michel Antonio Bueno Moraes for the illustrations support and Dr Assad Haffar from the World Federation of Haemophilia for contributing data regarding the WFH Humanitarian Aid Program.

Definitions in hemophilia: communication from the SSC of the ISTH

The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing

Hemophilia therapy: the future has begun

First-year results of an expanded humanitarian aid programme for haemophilia in resourceconstrained countries

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B

Production of high-potency concentrates of antihemophilic globulin in a closed-bag system

Home treatment for patients with haemophilia

Recombinant clotting factors

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

WFH Guidelines for the Management of Hemophilia

Defining extended half-life rFVIII-A critical review of the evidence

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B

Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B

Recombinant long-acting gly-coPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial

Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

Final results of PUPs A-LONG study: evaluating safety and efficacy of rFVIIIFc in previously untreated patients with haemophilia A

Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A

Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A

Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, nonrandomised phase 3 study

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

A multicentre, openlabel study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors

Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery

Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET

Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence

A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Long-term Safety and Efficacy of the Anti-TFPI Monoclonal Antibody Marstacimab in Patients with Severe Hemophilia A or B: Results from a Phase 2 Long-term Treatment Study

Longer-term Efficacy and Safety of Concizumab Prophylaxis in Hemophilia A and Hemophilia A/B with Inhibitors: Results from the Main and Extension Parts of Concizumab Phase 2

Safety and Efficacy of Concizumab Prophylaxis Following a Switch from rFVIIa on-demand Treatment: Sub-analysis Results from the Phase 2 Explorer4 Trial in Patients with Hemophilia A or B with Inhibitors

Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)

an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia: first results from a phase 3 study to evaluate efficacy and safety in people with hemophilia A or B without inhibitors (ATLAS-A/B)

Design and characterization of an APCspecific serpin for the treatment of hemophilia

Centessa Pharmaceuticals announces positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B patients not on prophylaxis 2021

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

Long-term safety and efficacy of factor IX gene therapy in hemophilia B

Adenovirusassociated virus vector-mediated gene transfer in hemophilia B

Hemostatic response is maintained for up to 5 years following treatment with valoctocogene roxaparvovec, an AAV5-hFVIII-SQ gene therapy for severe hemophilia A

Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A

Efficacy and Safety of Valoctocogene Roxaparvovec Adeno-associated Virus Gene Transfer for Severe Hemophilia A: Results from the Phase 3

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a

Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B

Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy

Evolution of AAV vector gene therapy is ongoing in hemophilia. Will the unique features of BAY 2599023 address the outstanding needs?

Five year Data Confirms Stable FIX Expression and Sustained Reductions in Bleeding and factor IX use Following AMT-060 Gene Therapy in Adults with Severe or Moderate-severe Hemophilia B

Etranacogene dezaparvovec (AAV5-Padua hFIX variant, AMT-061), an enhanced vector for gene transfer in adults with severe or moderate-severe hemophilia B: 2.5 year data from a phase 2b trial

Clinical Outcomes in Adults with Hemophilia B with and without Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data from the Phase 3 Etranacogene Dezaparvovec HOPE-B Gene Therapy Trial

Factor IX Expression within the Normal Range Prevents Spontaneous Bleeds Requiring Treatment Following FLT180a Gene Therapy in Patients with Severe Hemophilia B: Long-Term Follow-up Study of the B-Amaze Program

AAV5-Factor VIII Gene Transfer in Severe Hemophilia A

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A

Hemophilia gene therapy-New country initiatives

Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns

Observations from Global Survey 2001: an emerging database for progress

Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates

World Federation of Hemophilia

Adoption of emicizumab (Hemlibra(R)) for hemophilia A in Europe: Data from the 2020

European Association for Haemophilia and Allied Disorders survey

htm?produ ctId= 4889d 5d4-c688-4db5-8805-12a57 b1c95a1. Accessed

Disruptive technology and hemophilia care: The multiple impacts of emicizumab

Real-world cost estimates of initiating emicizumab in US patients with haemophilia A

Coordenação de gestão de protocolos clínicos e diretrizes terapêuticas -CPCDT/CGGTS/DGITIS/SCTIE/MS. Protocolo de uso do emicizumabe para tratamento de indivíduos com hemofilia A e inibidores do fator VIII refratários ao tratamento de imunotolerância

World Federation of Hemophilia

Feasibility and outcomes of low-dose and low-frequency prophylaxis with recombinant extended half-life products (Fc-rFVIII and Fc-rFIX) in Ivorian children with hemophilia: two-year experience in the setting of World Federation of Haemophilia Humanitarian Aid Programme

Low-dose surgical prophylaxis: optimization of use of World Federation of Hemophilia Humanitarian Aid donated clotting factor concentrates to developing countries

Emicizumab prophylaxis and monitoring: real world data

Is zero bleeds in pwh an achievable goal? 3 years of emicizumab in persons with hemophilia A and inhibitors in a Portuguese hemophilia treatment centers

A bleed suppression efficacy of emicizumab in patients with hemophilia A whose therapies switched from conventional prophylaxis

Real world experience with emicizumab with hemophilia A treated in private practice in Mexico

Real life use of emicizumab in pediatric patients without inhibitors

Real-world experience in introducing emicizumab prophylaxis for adults with haemophilia A without inhibitors

Decreased annual bleeding rate in paediatric patients with hemophilia a and inhibitors treated with emicizumab vs bypassing agents experience at the National Institute of Pediatrics

Efficacy and safety of emicizumab prophylaxis in severe haemophilia A without Inhibitors: a report from the UK Haemophilia Centre Doctors' Organisation (UKHCDO)

Emicizumab in the treatment of adult haemophilia patients real-world data

Real-world experience of emicizumab treatment using entire vials only

Emicizumab dosing in children and adults with hemophilia A: simulating a userfriendly and cost-efficient regimen

Efficacy of reduced-dose emicizumab in haemophilia A with inhibitors: real world experience in East Malaysia

Liver safety case report from the phase 3 HOPE-B Gene Therapy Trial in adults with hemophilia B

First-in-human phase 1/2 clinical trial of SIG-001, an innovative shielded cell therapy platform, for hemophilia Α

A next generation recombinant factor viii for subcutaneous hemophilia A prophylaxis

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice

Liver-directed lentiviral gene therapy in a dog model of hemophilia B

WFH State-of-the-art paper 2020: in vivo lentiviral vector gene therapy for haemophilia

Treatment of hemophilia a using factor VIII messenger RNA lipid nanoparticles

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

Nonacog beta pegol (N9-GP) in haemophilia B: a multinational phase III safety and efficacy extension trial (paradigm4)

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials

Updated follow-up of the Alta Study, a phase 1/2, open label, adaptive, dose-ranging study to assess the safety and tolerability of SB-525 gene therapy in adult patients with severe hemophilia A

A novel adeno associated virus (AAV) gene therapy (FLT180a) achieves normal FIX activity levels in severe hemophilia B (HB) patients (B-AMAZE Study)

Impact of novel hemophilia therapies around the world